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Abstract 
Objective: Compromised brain cholesterol turnover and altered regulation of brain cholesterol metabolism have 
been allied with some neurodegenerative diseases, including Huntington’s disease (HD). Following our previous stud‑
ies in HD, in this study we aim to investigate in vitro in a neuroblastoma cellular model of HD, the effect of CYP46A1 
overexpression, an essential enzyme in cholesterol metabolism, on huntingtin aggregation and levels.
Results: We found that CYP46A1 reduces the quantity and size of mutant huntingtin aggregates in cells, as well 
as the levels of mutant huntingtin protein. Additionally, our results suggest that the observed beneficial effects of 
CYP46A1 in HD cells are linked to the activation of autophagy. Taken together, our results further demonstrate that 
CYP46A1 is a pertinent target to counteract HD progression.
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Introduction
Huntington’s disease (HD), is an autosomal dominant 
inherited neurodegenerative disorder [1, 2], resulting 
from an abnormal CAG-repeat expansion in the coding 
region of the HTT gene, resulting in an expanded poly-
glutamine (polyQ) tract of the huntingtin protein (HTT) 
[3]. HTT protein gains a toxic function, and abnormally 
accumulates in the cells leading to their death [4, 5]. Clin-
ically, HD is associated with degeneration of the striatum 
and cerebral cortex [6–8], and symptoms such as uncon-
trolled movements, chorea, dystonia and oculomotor 
impairments [9]. Until now there is no therapy available 
to delay or stop HD progression [10].
Several studies have demonstrated that cholesterol 
metabolism impairment in the brain could be impli-
cated in different neurodegenerative diseases [11, 12]. 
Brain cholesterol is crucial for brain homeostasis and 
physiology, throughout development and in the course 
of neuronal lifespan [13, 14]. Brain cholesterol is nearly 
absolutely synthesized in situ [15], given that the blood-
brain-barrier (BBB) precludes its efflux/influx [16]. 
24-hydroxylase (CYP46A1), a key enzyme in cholesterol 
turn over and clearance is mostly expressed in neurons 
and hydroxylates cholesterol into 24S-hydroxycholesterol 
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(24S-OHC) that freely crosses the BBB reaching periph-
eral circulation [17]. CYP46A1 also play an important 
role in neural homeostasis [17–20]. It has been shown 
that CYP46A1 deficiency leads to neuronal dysfunc-
tion, neuronal death, motor and cognitive impairments 
and that CYP46A1 overexpression improved neurode-
generative HD-related traits [21–24]. Previously, we and 
others showed that cholesterol metabolism is impaired 
in HD, and strategies to reactivate it, such as CYP46A1 
expression restoration, show beneficial effects in differ-
ent HD model mice, including an improvement in neu-
ronal function, a prevention in neuronal degeneration 
and the recovery of motor deficits [22, 24–29]. Here, we 
investigated the impact of CYP46A1 overexpression in 
huntingtin aggregates and soluble mutant HTT (HTT-
MUT) levels and characterized a potential molecular 
mechanism.
Main text
Materials and methods
Neuroblastoma cells culture and transfections
Mouse neuroblastoma cell line (N2a cells; ATCC ® CCL-
131) were maintained at 37  °C, 5%  CO2, in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented 
with 10% foetal bovine serum, 100 U/ml penicillin and 
100 mg/ml streptomycin (Gibco). The different plasmids 
used were transfected in the cells using PEI (Polyethylen-
imine, #274651, Polysciences Inc.) in total concentration 
of 500  ng for each DNA. Cells were lysed for Western 
blot processing, harvested for flow cytometry analy-
sis or fixed for fluorescence microscopy analysis, 48  h 
post-transfection.
Plasmids
Plasmids used: pEGFP-HTTQ74 (Addgene #40262, 
exon 1 of HTT with 319  bp) [30], pAAV-HA-CYP46A1 
(provided by Brainvectis), ptfLC3-RFP-GFP (Addgene 
#21074) [31]. The LacZ gene was cloned in our laboratory 
under the control of a PGK promoter [32].
Western blot
The Western blot processing was performed as described 
previously [33]. Antibodies used for immunoblotting: 
mouse anti-GFP (1:1000, Biolegends, #668205), rabbit 
anti-LC3B (1:1000, Novus, #NB100-2220), rabbit anti-
p62/SQSTM1 (1:1000, Cell Signaling, #5114), mouse 
anti-ubiquitin (1:1000, Cell Signaling, #3936), mouse 
anti-β-tubulin, (1:10,000, Sigma-Aldrich, #T7816) and 
mouse anti-actin (1:10,000, Sigma-Aldrich, #A5316).
Immunocytochemistry
Immunocytochemistry was performed based on proto-
cols described previously [33]. Primary antibodies were 
incubated overnight at 4  °C (haemagglutinin (HA) tag, 
1:1000, Abcam, #ab9110). Secondary antibodies were 
incubated for 2  h at room temperature (Alexa 594 or 
Alexa 647, Thermo Fisher).
Fluorescence microscopy analysis
Mutant HTT aggregates were directly counted in a blind 
fashion way in 100 random cells with 40X objective in a 
Zeiss Axio Imager Z2. For the aggregate’s areas assess-
ment, the CellProfiler software was used [34]. Images 
were acquired with 40X objective in a Zeiss Axio Imager 
Z2. For the immunocytochemistry experiments, the LC3-
GFP-RFP puncta was blindly counted in 100 random cells 
with 40X objective in a Zeiss Axio Imager Z2.
Chloroquine treatment
We performed the chloroquine (ChQ) treatment 
(SIGMA, 100 μm), an inhibitor of autolysosomal degra-
dation, as previously described [33].
Ubiquitin‑proteasome system (UPS) inhibition 
in neuroblastoma cells
Six hours prior to collection (and 42 h post-transfection), 
transfected N2a cells were treated with MG-132 (Sigma-
Aldrich, 5  μM), an UPS inhibitor. After this treatment 
N2a cells were collected for western blot analysis.
Flow cytometry
Transfected cells were twice washed with PBS and then 
carefully harvested in PBS on ice. The different condi-
tions were then processed in a flow cytometer (Bec-
ton–Dickinson FACSCalibur) using the adequate lasers, 
as previously described [35]. Briefly, for each condi-
tion 50,000 cells were acquired in the selected gate, and 
positive cells were plotted as GFP fluorescence intensity 
(FL1 channel, 530 ± 30 nm).
Statistical analysis
Statistical analyses were performed using One-way 
ANOVA analysis with Bonferroni’s multiple comparisons 
test or unpaired t-Student test. Results are expressed as 
mean ± SEM. Significant thresholds were set at *P < 0.05, 
**P < 0.001, ***P < 0.0001, ****P < 0.00001. All analyses 
were performed using GraphPad Prism (GraphPad Soft-
ware v6, La Jolla, USA).
Results
We analyzed by immunocytochemistry the impact of 
CYP46A1 overexpression in neuroblastoma (N2a) cells 
overexpressing the exon 1 of HTT-MUT carrying 74 glu-
tamine (Q74) fused with GFP. N2a cells were co-trans-
fected with plasmids encoding HTT-MUT and either the 
plasmid encoding CYP46A1 or as control the plasmid for 
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lacZ (Fig. 1a). Approximately 90% of all transfected cells 
express both plasmids, without difference in cell viabil-
ity. We observed that the overexpression of CYP46A1 
(labeled with HA tag) significantly reduced the number 
of cells with HTT-MUT aggregates compared to HTT-
MUT condition and to HTT-MUT and lacZ (Fig.  1b). 
The aggregates area (µm2) was also significantly reduced 
upon CYP46A1 expression (Fig.  1c), as compared to 
HTT-MUT, and to HTT-MUT + lacZ. Next, we evalu-
ated the impact of CYP46A1 overexpression in the pro-
tein levels of HTT-MUT. Western blot analysis of N2a 
lysates using anti-GFP antibody showed a statistically 
Fig. 1 CYP46A1 overexpression decreases the number of aggregates and the levels of soluble mutant HTT. a N2a cells were transfected with 
pEGFP‑HttQ74, co‑transfected with pEGFP‑HttQ74 and pAAV‑HA‑CYP46A1, and co‑transfected with pEGFP‑HttQ74 and LacZ, highlighting the 
fusion protein with GFP, the nuclei labeled with DAPI and the expression of CYP46A1 by the labeling with HA tag. For each condition, 100 cells were 
randomly counted. b The number of cells with aggregates (white arrows) upon CYP46A1 overexpression was significantly reduced compared to 
control conditions (note the yellow arrows with expression of HTT‑MUT without aggregates). c The size of HTT‑MUT aggregates was smaller upon 
CYP46A1 overexpression relatively to both control conditions. d Western blot analysis probed with mouse anti‑GFP depicting the soluble HTT‑MUT 
(66 kDa) and tubulin as loading control. Densitometric analysis showed that CYP46A1 expression leads to a significant reduction of the soluble 
HTT‑MUT (e). Values are expressed as mean ± SEM. (a–c, n = 5 independent experiments; d–e, n = 4 independent experiments; One‑way ANOVA 
with Bonferroni’s multiple comparisons test, *P < 0.05; **P < 0.001; ****P < 0.00001)
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significant reduction in the levels of soluble HTT-MUT 
in the condition with CYP46A1, as compared to both 
control conditions (Fig.  1d–e). Altogether, these results 
show a robust effect of CYP46A1 in reducing the levels of 
HTT-MUT aggregates and protein.
To further investigate the mechanisms of CYP46A1-
mediated effects in the clearance of HTT-MUT via 
autophagic pathway experiments were preformed using 
a plasmid expressing the autophagic protein LC3B 
fused with RFP or GFP, and using an autophagy inhibi-
tor (chloroquine—ChQ; Fig.  2a) [31]. We found that 
CYP46A1 significantly increased both LC3-GFP and 
LC3-RFP puncta, as compared to control conditions 
(Fig. 2b;). This increase was even more pronounced than 
the one observed in the starvation condition, which is a 
positive control for autophagy activation, thus suggest-
ing that CYP46A1 is activating autophagy. We also per-
formed a cytometry analysis using cells transfected with 
the LC3-GFP-RFP plasmid. We observed that CYP46A1 
overexpression leads to a significant reduction in GFP 
fluorescence intensity compared to the control condi-
tion (Fig.  2c). As this experiment was performed in the 
absence of ChQ, the results suggest that CYP46A1 is acti-
vating autophagy, and promoting autophagy degradation, 
which could explain the observed reduction in the levels 
of HTT-MUT aggregates and protein.
Next, we analyzed the impact of CYP46A1 in several 
autophagy markers by western blot (Fig. 3a). Overexpres-
sion of CYP46A1 significantly increases LC3B-II levels 
compared to control condition (Fig. 3b), thus suggesting 
an activation of autophagy. Moreover, in the presence of 
ChQ the results follow the same trend. SQSTM1/p62 is 
a protein involved in the degradation of autophagy via a 
specific interaction between p62 and LC3 [44]. Impor-
tantly, a significant reduction in the SQSTM1/p62 levels 
was observed upon CYP46A1 overexpression, as com-
pared to the control condition (Fig.  3c), suggesting an 
increase in autophagic activity. Next, we calculated the 
autophagic flux by measuring the LC3B turnover assay, 
which is used to quantify the amount of LC3B-II that 
is delivered to the lysosomes and thus the autophagy 
dynamics. We found that CYP46A1 overexpression leads 
to a significant increase in the autophagic flux, as com-
pared to the control condition (Fig. 3d). To assess selec-
tive autophagy activation by CYP46A1, we performed an 
experiment inhibiting the ubiquitin–proteasome system 
(UPS) using MG132, which leads to the accumulation 
of polyubiquitinated proteins (Fig.  3e). The CYP46A1 
overexpression reduced the levels of HTT-MUT inde-
pendently of UPS inhibition (Fig.  3f ). Altogether, all 
these results suggest that CYP46A1 is able to activate 
autophagy pathway in a cellular model of HD.
Discussion
Impaired brain cholesterol metabolism has been broadly 
associated with neurodegenerative disorders. We and 
others showed that strategies aiming at restoring choles-
terol metabolism using different strategies are beneficial 
in AD, SCA and HD mouse models [22, 24, 36, 37]. Local 
synthesis/efflux of cholesterol is essential for the struc-
tural regulation of cells and membranes within the brain, 
being implicated in signal transduction, release of neuro-
transmitters and membrane trafficking [38]. Cholesterol 
has not the ability to cross the blood–brain-barrier (BBB). 
In order to be eliminated by the brain, therefore allowing 
brain cholesterol homeostasis, the excess of cholesterol is 
converted by the 24-hydroxylase (exclusively expressed 
in neurons) into 24-OHC that crosses the BBB, allowing 
brain cholesterol efflux [39, 40].
We have previously shown that CYP46A1 expression 
was able to reduce the number and size of intranuclear 
protein aggregates within the striatum of HD mouse 
models and improve motor impairment [22], emphasiz-
ing the neuroprotective effect conferred by CYP46A1 in 
HD mice [22, 24]. Here, we further show that CYP46A1 
is able to decrease the number and size of HTT-MUT 
aggregates within a neuroblastoma cellular model of 
HD. Furthermore, reduction of soluble HTT-MUT was 
decreased upon CYP46A1 overexpression. Autophagy is 
impaired in HD [41] and activating autophagy by express-
ing CYP46A1, may in part explain how inclusions and 
protein levels are decreased. We previously showed in a 
SCA3 in vitro and in vivo models that CYP46A1 robustly 
(See figure on next page.)
Fig. 2 CYP46A1 overexpression significantly increases the number of LC3 puncta upon autophagy inhibition. a N2a cells were transfected with 
ptfLC3‑RFP‑GFP, co‑transfected with ptfLC3‑RFP‑GFP and CYP46A1, and co‑transfected with ptfLC3‑RFP‑GFP and lacZ. An additional condition 
was used, promoting starvation, as a positive control for autophagy activation. The visualization of LC3‑puncta is possible upon autophagy 
inhibition with chloroquine in all the experimental conditions. The presence of LC3‑RFP‑GFP puncta (co‑localized) refers to the presence of 
mature autophagosomes, whereas LC3‑RFP puncta (without GFP) refers to autolysosomes. Representative microscopy images. b For each 
condition 100 cells were randomly counted in different microscopy fields. The number LC3‑puncta per cell upon CYP46A1 overexpression was 
significantly increased compared to both control conditions. c The total fluorescence intensity (GFP) was significantly reduced upon CYP46A1 
overexpression, compared to control conditions, thus suggesting an increase in the autophagic clearance. Values expressed as mean ± SEM. (a, b, 
n = 5 independent experiments, two‑way ANOVA with Bonferroni’s multiple comparisons test, *P < 0.05; ***P < 0.0001; ###P < 0.0001 comparing to 
LC3 + lacZ; c, n = 3 independent experiments Unpaired Student’s t test, ****P < 0.00001)
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increased the autophagic flux, i.e., augmented the levels 
of LC3-II and decreased the p62/SQSTM1 levels [36].
It is important to point that several studies have previ-
ously shown that the activation of autophagy, both using 
molecular or pharmacological approaches, is effective in 
removing HTT-MUT, and other mutated polyglutamine 
proteins, being therefore a privileged target for the devel-
opment of effective therapeutic approaches [42–44, 33, 
45–49].
Altogether, our data suggest that CYP46A1 degrades 
HTT-MUT via autophagy and that CYP46A1 may be a 
good target to alleviate HD progression. Therefore, our 
findings and our previous studies suggest that CYP46A1 
is implicated in HTT-MUT degradation via autophagy.
Limitations
Cellular models display several limitations and in  vivo 
studies must be perform as robust platforms for dis-
ease modelling supporting CYP46A1 in the activation of 
autophagy. Furthermore, additional studies of autophagy 
could be performed in this cellular model, including with 
additional controls, to further strengthen the observed 
results.
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